GLOBAL BLOOD THERAPEUTICS INC

GBT NASDAQ

PennyStock101

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D....

hutsell_andrew

GBT is in the midst of a cup and handle pattern. The handle has a bullish inverse head and shoulders pattern in it. It would be good to see the stock close above $63.50 and move past its early October high of ~$64. Similar to the other trades, start a 25% position and scale it up on price strength.

SpHiinX-BD

BUY

BigOonTheBeach

Volume and Price Action Study NASDAQ:GBT

BigOonTheBeach

Studying Price Action NASDAQ:GBT

RocketTickers

GBT: Global Blood Therapeutics, Inc. 2019-11-25 16:03:11 FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

ChaseWallace

Bearish count just to show that I know it's possible Green boxes for green abc Blue boxes for blue ABC I can update this into less scenarios and clean up the future price targets IF and WHEN wave B finishes. I don't know where that will be but if the price data confirms it, it'll give tagets for C before lift off.

ChaseWallace

A mediocre wave 3, 1:1 ratio of wave 1 - I don't see this scenario playing out but regardless selling at 85-86 to buy back in a big dip would be a good idea

ChaseWallace

1 bullish count, big 3rd wave Way too far in the future to be predicting price action but let's see

PennyStock101

Experts and analysts are falling over one another to upgrade GBT so it is no surprise it has had a beautiful run in 2019. Don't worry if you have missed out this is just the start, as commercialization becomes a reality. The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle...

kushrolled100

Continuing from previous post... It is safe to assume the area of 49-50 has strong support due to multiple down days bouncing back off those price levels. We finally broke through resistance at 53-54 levels but risk a gap-fill. Any dips below 53 should be momentary and needs to close above to continue upwards. Using fib-extensions from Mar 6 and Mar 28, I've...

kushrolled100

Retraced from highs and lows within the last 12 months and found the current price to be within an important zone... Above 50 is always a good sign and will eventually push if it holds. Line below price is it's support level. Under would reverse this.

UnknownUnicorn2993086

Waited for this. PT 52 wk highs. Short on $BLUE.

RocketTickers

GBT: Global Blood Therapeutics, Inc. 2018-12-03 10:00:00 GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile

carley621

We have a gap down trapping this bear flag. I like it to the first target, but if it really breaks down it's going to target 2 which is the 100MA on the weekly

winstox

Global Blood Therapeutics’ candidate (Voxelotor) has a lot of potential for SCD. There are a lot of articles on Sickle Cell Disease (SCD) which I strongly invite you to read. From a Technical Analysis point of view, I like what I see in GBT's chart. For me, the stock ended an a-b-c correction and is now preparing to move forward. Confirmation is needed but...

Ntandotrader

possible Head & Shoulders top on GBT, look to short below $38.80 and hlod towards $26.29 support.

DerekD_

I'll start this off with I have 0 positions in this company - only came across the ticker doing intra-day scans. I'll start with the most recent huge volume - peeped the news - apparently homeguy H.C Wainwright gives a $120 price target. Was trading $38.70 day before so I'm thinking this mf (since it's a biotech) got FDA approval on high blood pressure treatment...